Merck & Co., Inc. vs Prudential Financial Inc — how do they compare? Merck & Co., Inc. trades at $131.9 (market cap $321.77B), while Prudential Financial Inc trades at $121.73 (market cap $42.20B). The key difference: Merck & Co., Inc. is far larger — about 7.6× Prudential Financial Inc's market cap, and Prudential Financial Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| MRK | PRU | |
|---|---|---|
Market Cap | $321.77B | $42.20B |
Sector | Health | Financials |
52-Week High | $131.84 | $123.93 |
52-Week Low | $77.60 | $92.00 |
Enterprise Value | $368.53B | $70.98B |
Dividend Yield | 2.61% | 4.58% |
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.
The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.
Prudential Financial (PRU) trades at $122.11, up 0.68% today, with a bullish technical signal and strong Q2 2026 earnings beats. The stock shows solid fundamentals with a P/E of 11.09, ROE of 12.46%, and a $1.40 quarterly dividend. Recent news highlights strategic growth in wealth management and PGIM strength, though China tax concerns caused volatility.
Outlook is cautiously positive given earnings momentum and capital-light strategy, but risks include regulatory uncertainty in China and mixed analyst sentiment with 67.57% hold ratings. The consensus price target of $113.11 suggests limited upside from current levels, requiring monitoring of international operations.
Trailing returns across standard periods
Latest headlines on both assets
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →